Laboratory of Experimental Therapeutics (LIM-20), Department of Clinical Medicine, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
Front Immunol. 2021 Dec 9;12:804919. doi: 10.3389/fimmu.2021.804919. eCollection 2021.
The imbalance between pro- and anti-inflammatory immune responses mediated by Th17 and Treg cells is deeply involved in the development and progression of inflammation in chronic obstructive pulmonary disease (COPD). Several clinical and experimental studies have described the Th17/Treg imbalance in COPD progression. Due to its importance, many studies have also evaluated the effect of different treatments targeting Th17/Treg cells. However, discrepant results have been observed among different lung compartments, different COPD stages or local and systemic markers. Thus, the data must be carefully examined. In this context, this review explores and summarizes the recent outcomes of Th17/Treg imbalance in COPD development and progression in clinical, experimental and studies.
辅助 T 细胞 17(Th17)和调节性 T 细胞(Treg)介导的促炎和抗炎免疫反应失衡,与慢性阻塞性肺疾病(COPD)炎症的发生和发展密切相关。多项临床和实验研究描述了 COPD 进展过程中 Th17/Treg 失衡。由于其重要性,许多研究还评估了针对 Th17/Treg 细胞的不同治疗方法的效果。然而,不同肺区、不同 COPD 阶段或局部和全身标志物之间观察到的结果存在差异。因此,必须仔细检查这些数据。在此背景下,本综述探讨和总结了 Th17/Treg 失衡在 COPD 发展和进展中的最新临床、实验和研究结果。